Coppell Advisory Solutions LLC Has $3.22 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Coppell Advisory Solutions LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,042 shares of the biopharmaceutical company's stock after selling 2,556 shares during the quarter. Coppell Advisory Solutions LLC's holdings in Gilead Sciences were worth $3,224,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. MGO One Seven LLC grew its holdings in Gilead Sciences by 70.8% during the 4th quarter. MGO One Seven LLC now owns 11,195 shares of the biopharmaceutical company's stock valued at $1,034,000 after buying an additional 4,639 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Gilead Sciences by 5.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,546,721 shares of the biopharmaceutical company's stock valued at $327,612,000 after purchasing an additional 198,528 shares during the last quarter. Silverarc Capital Management LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at about $924,000. Alta Advisers Ltd grew its holdings in shares of Gilead Sciences by 16.4% during the 4th quarter. Alta Advisers Ltd now owns 4,192 shares of the biopharmaceutical company's stock worth $387,000 after purchasing an additional 592 shares during the period. Finally, Harvest Investment Services LLC purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $304,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total value of $14,073,240.72. Following the transaction, the chief financial officer now directly owns 171,223 shares of the company's stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 302,785 shares of company stock valued at $30,540,875. Corporate insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Piper Sandler raised their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research report on Thursday, February 13th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $108.42.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $2.98 during trading hours on Friday, reaching $103.17. 14,207,970 shares of the company's stock were exchanged, compared to its average volume of 7,526,289. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $128.46 billion, a P/E ratio of 278.84, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The business's 50-day simple moving average is $109.21 and its two-hundred day simple moving average is $98.15. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.73 by $0.08. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the business posted ($1.32) EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.06%. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.